Exagen Inc. (NASDAQ:XGN) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Exagen Inc. (NASDAQ:XGN) have earned an average recommendation of “Moderate Buy” from the nine analysts that are covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation and eight have issued a buy recommendation on the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $12.50.

XGN has been the subject of several recent analyst reports. KeyCorp upped their price objective on shares of Exagen from $12.00 to $15.00 and gave the stock an “overweight” rating in a report on Tuesday, October 14th. Weiss Ratings reissued a “sell (d-)” rating on shares of Exagen in a research report on Wednesday, January 21st. BTIG Research raised their price target on Exagen from $13.00 to $15.00 and gave the company a “buy” rating in a research report on Monday, November 10th. B. Riley Financial reiterated a “buy” rating and issued a $8.00 price objective (down from $18.00) on shares of Exagen in a research note on Friday, January 30th. Finally, Canaccord Genuity Group increased their target price on Exagen from $11.00 to $15.00 and gave the company a “buy” rating in a research note on Monday, October 27th.

Exagen Stock Up 4.5%

XGN opened at $3.51 on Friday. The business has a 50 day moving average price of $5.70 and a 200 day moving average price of $8.38. Exagen has a twelve month low of $2.67 and a twelve month high of $12.23. The company has a debt-to-equity ratio of 1.35, a quick ratio of 4.08 and a current ratio of 4.08. The firm has a market cap of $79.54 million, a P/E ratio of -3.82 and a beta of 1.90.

Institutional Investors Weigh In On Exagen

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Acadian Asset Management LLC bought a new stake in shares of Exagen in the 1st quarter worth approximately $25,000. Huntleigh Advisors Inc. raised its stake in shares of Exagen by 5.7% in the second quarter. Huntleigh Advisors Inc. now owns 87,861 shares of the company’s stock valued at $613,000 after purchasing an additional 4,753 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of Exagen by 45.6% in the second quarter. Geode Capital Management LLC now owns 146,483 shares of the company’s stock valued at $1,023,000 after purchasing an additional 45,884 shares in the last quarter. Calamos Advisors LLC bought a new position in Exagen in the second quarter worth $526,000. Finally, Citizens Financial Group Inc. RI bought a new position in Exagen in the second quarter worth $472,000. Institutional investors and hedge funds own 75.25% of the company’s stock.

Exagen Company Profile

Exagen Inc is a molecular diagnostics company focused on improving the detection and management of autoimmune diseases. Headquartered in the United States, the company develops, manufactures and markets laboratory tests designed to help clinicians address diagnostic challenges associated with complex connective tissue disorders.

The company’s flagship product portfolio, marketed under the Avise® brand, includes multi-analyte assays such as the Avise® Connective Tissue Disease (CTD) panel, Avise® Lupus panel and Avise® Sjögren’s panel.